Raymond James Financial Services Advisors Inc. Has $519,000 Holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Raymond James Financial Services Advisors Inc. cut its holdings in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 20.2% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 36,399 shares of the company’s stock after selling 9,229 shares during the period. Raymond James Financial Services Advisors Inc.’s holdings in Takeda Pharmaceutical were worth $519,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of TAK. Point72 Asset Management L.P. bought a new stake in Takeda Pharmaceutical during the fourth quarter worth about $43,410,000. Millennium Management LLC lifted its position in Takeda Pharmaceutical by 124.1% during the fourth quarter. Millennium Management LLC now owns 2,238,381 shares of the company’s stock worth $34,919,000 after purchasing an additional 1,239,382 shares during the period. BlackRock Inc. lifted its position in Takeda Pharmaceutical by 38.6% during the first quarter. BlackRock Inc. now owns 3,021,274 shares of the company’s stock worth $43,265,000 after purchasing an additional 842,139 shares during the period. Goldman Sachs Group Inc. lifted its position in Takeda Pharmaceutical by 13.7% during the first quarter. Goldman Sachs Group Inc. now owns 4,242,689 shares of the company’s stock worth $60,755,000 after purchasing an additional 509,886 shares during the period. Finally, Kayne Anderson Rudnick Investment Management LLC bought a new stake in Takeda Pharmaceutical during the first quarter worth about $7,800,000. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Takeda Pharmaceutical

In other news, major shareholder Pharmaceutical Co Ltd Takeda sold 3,703,703 shares of the stock in a transaction dated Wednesday, January 24th. The shares were sold at an average price of $8.10, for a total value of $29,999,994.30. Following the completion of the transaction, the insider now owns 3,755,583 shares of the company’s stock, valued at $30,420,222.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.04% of the company’s stock.

Takeda Pharmaceutical Trading Up 0.6 %

TAK opened at $13.24 on Friday. Takeda Pharmaceutical Company Limited has a twelve month low of $13.11 and a twelve month high of $17.11. The company has a 50-day simple moving average of $14.18 and a 200 day simple moving average of $14.26. The company has a quick ratio of 0.55, a current ratio of 1.06 and a debt-to-equity ratio of 0.64. The stock has a market capitalization of $41.90 billion, a price-to-earnings ratio of 20.06, a P/E/G ratio of 3.72 and a beta of 0.53.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Thursday, February 1st. The company reported $0.51 EPS for the quarter. The firm had revenue of $7.52 billion during the quarter. Takeda Pharmaceutical had a net margin of 6.90% and a return on equity of 12.57%. Analysts predict that Takeda Pharmaceutical Company Limited will post 1.5 EPS for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.